undamentalytics Newsletter
Sign in

Kymera Therapeutics, Inc. income statement

In fiscal 2025, Kymera Therapeutics, Inc. reported revenue of $39.2m, down 16.7% on the year before, operating income of −$349m (a -891.1% margin) and net income of −$311m, or −$3.69 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue3347347794739102
Cost of revenue———47794739102
Gross profit———00000
Research and development3762137164189240317430
General and administrative818364455646877
Operating income−42−46−101−161−166−262−349−405
Income before tax——————−311—
Income tax0000——0—
Net income−41−46−100−155−147−224−311−349
Diluted EPS−$2.43−$3.15−$2.09−$2.87−$2.52−$2.98−$3.69−$3.62
Diluted shares (average)17m17m48m54m58m75m84m96m
EBITDA−41−45−98−158−162−254−341−398

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KYMR vs XNCRKYMR vs SEPNAGIO vs KYMR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kymera Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kymera Therapeutics, Inc.